Preeclampsia Drugs Global Market New Business Opportunities to Hit $1.89 Billion By 2028 at a CAGR of 10.9%.| AbbVie Inc., Pfizer Inc., Novartis AG, Sanofi S.A., Celgene Corp

The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.13 billion in 2023 to $1.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increased maternal health awareness, research and development, neonatal health concerns, early detection.

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to personalized medicine, non-invasive diagnostic tools, targeted therapies, health equity initiatives. Major trends in the forecast period include preventive strategies, patient-centered care, continuous monitoring, regulatory focus.

Market Overview -
Preeclampsia drugs refer to medications that manage and treat the condition of pre-eclampsia, a serious pregnancy complication characterized by high blood pressure and damage to organs like the liver and kidneys. These drugs are typically prescribed by healthcare professionals to pregnant women diagnosed with preeclampsia to help lower blood pressure and prevent further complications.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Rising Diabetes Cases In Pregnancy Fueling Growth In The Preeclampsia Drug Market
The rise in diabetes cases among pregnant women is expected to propel the growth of the preeclampsia drug market going forward. Diabetes is a metabolic disease that is chronic and characterized by high blood glucose (or blood sugar) levels. Preeclampsia is a harmful pregnancy condition with elevated blood pressure and organ damage. Metformin, a preeclampsia medicine, is widely used in pregnant women with preterm preeclampsia. For instance, in December 2022, according to the National Library of Medicine, a US-based biomedical library and center of biomedical informatics, the total incidence of gestational diabetes mellitus (GDM) was 20,865 cases, an increase of 6.56% in 2022. Therefore, the rise in diabetes cases among pregnant women will drive the preeclampsia drug market.

Competitive Landscape -
Major players in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

Leading Companies In The Preeclampsia Medicine Market Pursuing Innovative Drug Solutions
Major companies in the preeclampsia medicine market are focusing on developing cutting-edge drug solutions to boost their market position. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, revealed that the Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for CBP-4888 Comanche's unique siRNA treatment to treat preeclampsia. CBP-4888 is a siRNA therapy given subcutaneously and reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The placenta's overproduction of the protein sFLT1, which enters the mother's circulation, is the primary cause of preeclampsia. CBP-4888 can alleviate the symptoms of preeclampsia, such as high blood pressure and organ damage and may allow for the safe extension of pregnancy.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Key Segments -
The preeclampsia drugs market covered in this report is segmented -
1) By Type: Mild Preeclampsia; Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P); Corticosteroids; Anticonvulsants Medication
3) By Route of Administration: Oral; Parenteral; Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
5) By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.